Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
Peter J. Richardson,Ivan Griffin,6 Authors,J. Stebbing
2020 · DOI: 10.1016/S0140-6736(20)30304-4
The Lancet · 1,245 Citations
TLDR
It is suggested that baricitinib could be trialled, using an appropriate patient population with 2019-nCoV acute respiratory disease, to reduce both the viral entry and the inflammation in patients, using endpoints such as the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia.